Distribution of Human Papillomavirus Genotype in Anal Condyloma Acuminatum Among Japanese Men: The Higher Prevalence of High Risk Human Papillomavirus in Men Who Have Sex with Men with HIV Infection

Furukawa, Satomi; Uota, Shin; Yamana, Tetsuo; Sahara, Rikisaburo; Iihara, Kuniko; Yokomaku, Yoshiyuki; Iwatani, Yoshinori; Sugiura, Wataru

doi:10.1089/aid.2017.0197

Cited by 9 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…e polypeptide hormone produced by thymic epithelial cells is called thymosin, which is an immunomodulator and is used in the treatment of CA by inducing T cell differentiation and regulating immune balance. Compared with thymosin injection, oral preparation has the advantages of good compliance and easy to take and carry, and the degree of acceptance of patients is higher [15][16][17]. Photodynamic therapy utilizes molecular oxygen induced by photosensitizer and light source to selectively break the ring of target tissue cells with 5-aminolevulinic acid.…”

Section: Discussionmentioning

confidence: 99%

A Case-Control Study of Photodynamic Therapy Combined with Thymosin in the Treatment of Condyloma Acuminatum in Anal Canal

Wang

Hong

2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

A case-control study is performed in this paper to explore various possible effects and clinical value of the photodynamic therapy combined with thymosin for the treatment process of the condyloma acuminatum (CA) in the anal canal. For this purpose, a hundred (100) patients specifically with CA in the anal canal who were regularly treated in the hospital from February 2019 to April 2021 were recruited. The first group, that is, the control group, was treated with thymosin, whereas photodynamic therapy combined with thymosin was used as a treatment for the study group. The curative effect, clinical index, LTN, SP, TGF-β 1, TNF-α, CD3+, CD4+, CD8+, and the adverse reactions of incidence were compared between these groups. Moreover, 27 cases were observed to be obviously effective, 22 were observed to be effective, and a single case was observed to be ineffective. Thus, 98% is the total effective rate where a single case relapses. Likewise, in the control group, 15 cases were observed to be obviously effective, 28 effective, and 13 ineffective. Thus, 86% is the total rate of effectiveness where thirteen (13) cases relapse. We have observed that the study group has a higher rate of effectiveness than the control group and the rate of recurrence of the former group was slightly lower than that of the latter group, that is, the control group ( P < 0.05). In addition, the time of symptom improvement, the amount of bleeding, the disappearance time of bloody stool, and the time of the first recurrence of the study group were observed to be lower than those of the control group ( P < 0.05). In levels of LTN and SP, we have observed no or zero significant differences between these groups before treatment. However, LTN’s levels of both groups increased after the treatment, and SP’s level decreased. LTN’s level of the study group was observed to be higher than that of the other group, and SP’s level in the former group was lower than that in the latter group. Zero significant differences were observed in the TGF-β 1 and TNF-α’s levels between these groups before treatment, but the level of TGF-β 1 and TNF-α has increased and decreased, respectively, in both groups specifically after treatment. The level of TGF-β 1 in the former group was observed to be slightly higher than that in the latter group, that is, the control group, while TNF-α’s level in the study group was lower than that in the control group. We have not observed any significant difference in CD4+, CD3+, and CD8+ levels between these groups before treatment. However, after treatment, CD3+ and CD4+ levels increased, and the levels of CD8+ decreased in both groups, while CD3+ and CD4+ levels in the former group were evident to be higher than those in the latter group and the level of the CD8+ in the study group was observed to be lower than that in the control group. Finally, we compared the adverse reactions of incidence between these groups. There were 4 cases of tingling sensation and 1 case of redness and swelling in the group study along with a total incidence of 10%. There were 5 cases of tingling sensation and 2 cases of redness and swelling in the control group along with a total incidence of 14%. The incidence of adverse reactions in the study group was observed to be slightly lower than that in the control group, but a significant difference was not observed between these groups (χ2 = 0.378; P > 0.05).

show abstract

Section: Discussionmentioning

confidence: 99%

A Case-Control Study of Photodynamic Therapy Combined with Thymosin in the Treatment of Condyloma Acuminatum in Anal Canal

Wang

Hong

2022

Journal of Healthcare Engineering

View full text Add to dashboard Cite

show abstract

“…Furukawa et al reported a high risk of serotype HPV with high grade squamous intraepithelial lesion (HSIL) leading to anal cancer from the anal CA tissue specimens in HIV-positive MSM patients in Japan. 6 In this case, the patient has a high-risk factor for anal CA in consideration of his sexual behavior. The patient was a bottom MSM, having an average of 2 sexual intercourse per week with multiple sexual partners and rarely used condoms.…”

Section: Discussionmentioning

confidence: 98%

“…4,5 Therefore, the incidence of anal cancer (squamous cells carcinoma) increases, especially in MSM with HIV. 6 The ideal therapy for CA should be simple, inexpensive, effective, and does not cause side effects. 2 Specific therapy is not yet available so that eradication is not maximal, causing a significant clinical problem and frequent recurrences.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of 5-Fluorouracil 5% Cream in Perianal Condylomata Accuminata Treatment: A Case Report

Florensia

Setyowatie

2021

BIKK

View full text Add to dashboard Cite

Background: Condylomata accuminata is a sexually transmitted disease, appeared as verrucous or cauliflower-like papules or warts in the anogenital. It is caused by human papillomavirus (HPV), mostly type 6 and 11. The ideal therapy should be simple, inexpensive, effective, does not cause side effects, and can be used by the patient himself. Purpose: To assess the effectiveness of 5-Fluorouracil (5-FU) 5% cream therapy for perianal condylomata accuminata treatment. Case: A 24-year-old male presented with a chief complaint of warts around the anal area that multiplied in the past 3 weeks. The acetowhite test was positive. The patient was diagnosed with condylomata accuminata perianal. The patient received 5-FU 5% cream, applied 3 times a week to the lesions for 5 weeks. After 5 weeks, no new warts were found. Discussion: 5-FU 5% cream is a therapeutic option for perianal wart lesions that easily applied, inexpensive, effective, does not cause side effects, and can be used by the patient himself. It is well known as an antimetabolite with a cytotoxic effect that occurs through a mechanism of disruption in the normal synthesis and function of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The treatment with 5-FU 5% cream 3 times a week for 5 weeks provided good results with no side effects were reported. Conclusion: The application of 5-FU 5% cream was a modality of self-application treatment that effective for perianal condylomata accuminata.

show abstract

“…The meta-analysis of anal HR-HPV and HPV-16 included eight studies, one each from United States [11], Brazil [12], Germany [13], Spain [14], Netherlands [15], Japan [16], Switzerland [17] and Taiwan [18] with a total of 525 cases (Table S1, http://links.lww.com/QAD/ C183, Figure S1, http://links.lww.com/QAD/C179, Fig. 1 and Figure S2, http://links.lww.com/QAD/ C180).…”

Section: Overall Anal High-risk Human Papilloma Virus and Human Papil...mentioning

confidence: 99%

High-risk human papilloma virus, precancerous lesions and cancer in anal condylomas

Albuquerque

Cappello

Stirrup

2021

Aids

View full text Add to dashboard Cite

Introduction: Anal condylomas are associated with human papillomavirus (HPV) infection and are a risk factor for anal squamous cell carcinoma (SCC).Objective: To conduct a meta-analysis evaluating the prevalence of anal high-risk HPV, high-grade squamous intraepithelial lesions (HSIL) and SCC in patients with condylomas. The standardized incidence ratio (SIR) and the incidence rate of anal SCC were also calculated.Methods: Three electronic databases were searched until April 2020. Meta-analyses were performed using random effects models.Results: Pooled prevalence estimate of high-risk HPV (HR-HPV) in anal condylomas was 40.2% (21.0-63.1) in immunocompromised and 16.4% (10.7-24.3) in nonimmunocompromised patients, with an odds ratio (OR) of 3.79 (1.51-9.52, P ¼ 0.005) for immunocompromised patients. HR-HPV in condylomas with HSIL was 73.8% (39.1-92.5) and in non-HSIL cases was 17.7% (9.6-30.2), corresponding to an OR of 12.33 (2.97-51.21, P ¼ 0.001) for those with HSIL. The prevalence of HSIL in condylomas was 24.0% (16.4-33.7) in immunocompromised and 11.8% (7.2-18.8) in nonimmunocompromised patients, with an OR of 2.51 (1.72-3.65, P < 0.001) for immunocompromised patients. The overall prevalence of anal SCC in anal condylomas was 0.3% (0.0-1.7).

show abstract

Distribution of Human Papillomavirus Genotype in Anal Condyloma Acuminatum Among Japanese Men: The Higher Prevalence of High Risk Human Papillomavirus in Men Who Have Sex with Men with HIV Infection

Cited by 9 publications

References 30 publications

A Case-Control Study of Photodynamic Therapy Combined with Thymosin in the Treatment of Condyloma Acuminatum in Anal Canal

A Case-Control Study of Photodynamic Therapy Combined with Thymosin in the Treatment of Condyloma Acuminatum in Anal Canal

Effectiveness of 5-Fluorouracil 5% Cream in Perianal Condylomata Accuminata Treatment: A Case Report

High-risk human papilloma virus, precancerous lesions and cancer in anal condylomas

Contact Info

Product

Resources

About